
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is expected to see strong sales revenue and growth potential from their recently approved ophthalmic formulation of bevacizumab, LYTENAVA, for the treatment of wet age-related macular degeneration (wAMD). With a lean sales force model and potential for additional biosimilar products, the company is well-positioned for success in the market. The recent approval and launch in Europe, along with a planned launch in the US, are expected to drive revenue growth, and the company has a strong balance sheet with enough cash to support operations into late-2026. The recent FDA appeal win and resubmission of their BLA, along with partnerships for market access and distribution, further support a positive outlook for the company.
Bears say
Outlook Therapeutics is facing a negative outlook due to several key factors. Lack of commercial momentum in Europe and uncertainty about potential FDA approval for LYTENAVA (ONS-5010) in the US make it difficult to have a positive outlook on the company. Additionally, the company is facing high risks and uncertainties in the drug development industry, including unexpected outcomes from clinical trials and challenges in navigating complex and price-sensitive commercial markets. These factors make it difficult to have confidence in the company's growth prospects and justify a BUY rating.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares